Inflammatory bowel disease (IBD) is a chronic relapsing disorder of the gastrointestinal tract that is driven by misled host-microbial interplay. In the past years we and others have contributed to multi-omics analysis of inflammatory bowel disease, which has painted a multifaceted picture of this complex immune-mediated disorder. However, a thorough understanding of the molecular causations that lead to manifestation and result in pathological cytokine signalling is still lacking. Recent findings underscore a potential role for the host – microbial metabolite axis in establishing mucosal homeostasis. However, disturbances in specific metabolic pathways (e.g. tryptophan, short-chain fatty acids) can also contribute to disease pathogenesis of IBD. Our groups aims to integrate a focused metabolic understanding into multi-omics models to elucidate pathophysiological key features of immune-metabolic crosstalk in IBD. To that purpose our group combines longitudinal biosamples from IBD patients, mouse models of intestinal inflammation (genetic, chemical), intestinal organoid cultures (human/murine) and state of the art molecular cell biology to identify novel immune-metabolic principles that contribute to the pathophysiology of IBD.
The group is always interested in motivated MD student to conduct their MD thesis in basic and translational research.